MRI in High-Grade Glioma Patients Undergoing Chemoradiation
Part of paid clinical trials in Winston-Salem, North Carolina.
- Sponsor
- Wake Forest University Health Sciences
- Study ID
- NCT05212272
- Status
- Recruiting
Conditions
- High Grade Glioma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- PET-MRI Brain Scan — PROCEDUREBefore starting radiation, participants will have a PET scan and MRI scan of the brain. After 2 to 3 weeks of radiation treatments, participants will have a repeat PET scan. Then 1 month after radiation participants will have another PET scan
- Blood draw — DIAGNOSTIC_TESTBlood draws will be taken at baseline, one month after radiation treatment and 3 to 4 months after radiation treatment.
- Memory testing — BEHAVIORAL3 sessions with simple tests to evaluate how the brain is working. These tests primarily check things like memory, attention, and thought process. The whole set of tests will take 1 hour each time.
- Optional lumbar puncture for cerebrospinal fluid collection — PROCEDUREParticipants that consent for cerebrospinal fluid collection will have 6 and 20 ml of cerebrospinal collected at baseline.
Study Details
The purpose of this research study is to see if investigators can predict how brain functioning changes after radiation treatment based on PET scans and blood tests. Most participants experience at least mild decreases in their memory or attention after radiation therapy. Investigators hope that PET scans, lumbar puncture, and blood tests might help investigators predict who might have larger changes in their brain function after radiation.
Key Dates
- Start date
- Sep 2, 2022
- Status verified
- Mar 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 16 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- DIAGNOSTIC
Arms
- Experimental: PET-MRI In High-Grade Glioma Patients Undergoing ChemoradiationPET scan and MRI scan of the brain, blood draw, and 1-hour of memory testing.
Primary Outcome Measure
Number of Participants to Complete Two PET scans [ Time Frame: At baseline and at 4 months post-treatment ]
Central Contacts
- Study Coordinator336-716-5772
- Study Nurse336-713-3539
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem | North Carolina | 27157 | Christina Cramer, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Winston-Salem, NC
Related Studies
- A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK FusionEARLY_PHASE1 · Recruiting · Nationwide Children's Hospital · Aurora, Colorado
- PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent MedulloblastomaPHASE2 · Recruiting · Nationwide Children's Hospital · Aurora, Colorado
- Targeted Pediatric High-Grade Glioma TherapyRecruiting · Nationwide Children's Hospital · Aurora, Colorado
- Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutantPHASE2 · Recruiting · Nationwide Children's Hospital · Aurora, Colorado